Biogen IDEC - Product Websites AMEVIVE® (alefacept) AMEVIVE is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.alefacept) included: sore throat, dizziness,...
Biogen Idec - Customer Support Insurance specialists help patients taking AVONEX® (Interferon beta-1a), RITUXAN® (rituximab), ZEVALIN® (ibritumomab tiuxetan) and AMEVIVE® (alefacept) with insurance coverage issues.
Biogen Idec - Products on the Market AMEVIVE® (alefacept) AMEVIVE is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.AMEVIVE reduces the number of T cells, which are one of the body's ways to fight off disease.AMEVIVE, be sure to tell your doctor if...
Biogen Idec - History home | contact info | locations | site map investor relations | careers Company + Management - Vision and Values + Investor Relations + News and Media - Corporate Governance + Careers - History - New Ventures + Strategic Alliances + Community Relations Products Patients History In June 2003, Biogen and IDEC Pharmaceuticals announced their agreement to merge.
Immune system medications for psoriasis - [Medication] - Quest Diagnostics Patient Health Library Immune system medications for psoriasis Examples A shot (injection) or IV (intravenous) Brand Name Chemical Name Amevive alefacept Alefacept is taken once a week in an IV (intravenously) or once a week as a shot (intramuscular injection).Alefacept and efalizumab block harmful responses from the body's immune system that lead to the symptoms of...
Adult Health Advisor 2004.2: Psoriasis Adult Health Topics | All Health Topics Find a UMHS Doctor Search Adult Topics Search All Topics This information is approved and/or reviewed by U-M Health System providers but it is not a tool for self-diagnosis or a substitute for medical treatment.
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Btech Investor Inc - News archive 2 - - - - BioNews BioWeb Companies Products BioReports - - - - - - Marketing approval for Biogen's (NASDAQ: BGEN) Amevive (alefacept) - treatment of moderate-to-severe chronic plaque psoriasis.
BioPortfolio Client Press Releases Site Map UK Universities choose 2D image analysis solutions from Nonlinear Dynamics BioPortfolio BioNews (News & Press Releases) January 2003 Biotech Tracker News - Amevive Approved Biotech Tracker News - Bringing Microarrays to the Clinic Syncroscopy New Plug and Play Microscope Cameras Software Integration offers Outstanding Colour Imaging for Microscopists Danish LEO Pharma Obtains...
Marketing approval for Biogen's (NASDAQ: BGEN) Amevive (alefacept) - treatment of moderate-to-severe chronic plaque psoriasis. - - - - BioNews BioWeb Companies Products BioReports - - - - - Marketing approval for Biogen's (NASDAQ: BGEN) Amevive (alefacept) - treatment of moderate-to-severe chronic plaque psoriasis.Amevive (alefacept) for the treatment...
Biogen Receives Complete Response Letter For Amevive - - - - BioNews BioWeb Companies Products BioReports - - - - - Biogen Receives Complete Response Letter For Amevive The FDA has asked Biogen (NASDAQ: BGEN) for "clarification and information related to previously-submitted data" regarding Amevive (alefacept), its anti-psoriasis drug.
Biotech Tracker News - Raptiva BLA Filed - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - Raptiva BLA Filed December 24, 2002 Genentech (NYSE: DNA ) and Xoma (NASDAQ: XOMA ) submitted a BLA for Raptiva (efalizumab) for the treatment of moderate-to-severe plaque psoriasis.Amevive (alefacept) is likely to receive FDA consideration by the end...
Biotech Tracker News - Amevive Approved - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - Amevive Approved - January 31, 2003 Today, Biogen’s (NASDAQ: BGEN) Amevive (alefacept) became the first FDA-approved biological product for the treatment of adults with moderate-to-severe chronic plaque psoriasis.
Biotech Tracker News - European Approval of Amevive Delayed - - - - BioNews BioWeb Companies Products BioReports - - - - - - Biotech Tracker News - European Approval of Amevive Delayed - February 20, 2003.- The Committee for Proprietary Medicinal Products (CPMP), the scientific advisors to the European Medicines Evaluation Agency (EMEA), has requested additional information regarding Biogen’s (NASDAQ: BGEN) Amevive (...
BioPortfolio BioNews (News & Press Releases) Jan to May 02 - - - - BioNews BioWeb Companies Products BioReports - - - - - - Rad Bioscience Wins Israel’s Biotechnology Incubator Competition Tracleer Efficacious in Children for treatment of pulmonary arterial hypertension (PAH) Platform Technology vs.Amevive (alefacept) - treatment of moderate-to-severe chronic plaque...
BIOTECanada - Member News Welcome to the new Member News Archives.
Database A A - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 54
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 12
Therapeutic Biological Approvals Laronidase has not been evaluated for effects on the central nervous system manifestations of the disorder 125058 / 0 Biomarin Pharmaceutical Inc 371 Bel Marin Keys Boulevard Suite 210 Novato, CA 94949 License 1649 4/30/2003 Amevive Alefacept Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or...
New Topics Clinical Laboratory Immediate Response Mobile Analysis (IRMA) System for Home Use Electrolyte Monitoring Irradiation Indicators (RAD-SURE) for Visual Confirmation of Gamma Irradiated Blood Products Portable Devices (CoaguChek and Protime Microcoagulation Systems) for Home Oral Coagulation Monitoring Dentistry and Oral Surgery Dental Appliances for Sleep Apnea Diagnosis and Treatment...
Pharmaceutical Research and Manufacturers of America - Psoriasis Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Alicaforsen (ISIS 2302) none / none Psoriasis Ulcerative Colitis ISIS Pharmaceuticals Carlsbad, CA Phase III/Phase II/Phase II 12 years and older - ...
Pharmaceutical Research and Manufacturers of America - Biogen Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes Adentin none / adenosine A1 antagonist Congestive Heart Failure Biogen Cambridge, MA Phase II - Adentri (adenosine A1 antagonist) none / none Acute and...
Product Approval Letter - Alefacept, Amevive, Biogen, Inc Under this authorization, you are approved to manufacture Alefacept at your facilities in Cambridge, Massachusetts and Research Triangle Park, North CarolinaAlefacept Alefacept in the HIV population when more data on the long-term...
